Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will host a virtual key opinion leader (KOL) event highlighting the current state of lung cancer treatments and the challenges facing patients.
Genprex, Inc. (NASDAQ:GNPX – Get Free Report) was the recipient of a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,650,000 shares, a drop of 6.8% from the September 15th total of 1,770,000 shares. Based on an average daily volume of 540,900 shares, the […]
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.